S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
NASDAQ:SUPN

Supernus Pharmaceuticals Stock Forecast, Price & News

$29.02
-0.33 (-1.12%)
(As of 01/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$28.87
$29.66
50-Day Range
$28.00
$33.47
52-Week Range
$23.15
$34.50
Volume
367,969 shs
Average Volume
380,371 shs
Market Capitalization
$1.53 billion
P/E Ratio
19.22
Dividend Yield
N/A
Beta
1.16
30 days | 90 days | 365 days | Advanced Chart
Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Supernus Pharmaceuticals logo

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Headlines

Supernus Pharmaceuticals Targeted in Ransomware Incident
November 24, 2021 |  finance.yahoo.com
Supernus Announces Third Quarter 2021 Financial Results
November 3, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:SUPN
CUSIP
86845910
Employees
563
Year Founded
N/A

Sales & Book Value

Annual Sales
$520.40 million
Cash Flow
$2.88 per share
Book Value
$14.14 per share

Profitability

Net Income
$126.95 million
Pretax Margin
19.64%

Debt

Price-To-Earnings

Miscellaneous

Free Float
48,644,000
Market Cap
$1.53 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2021
Today
1/28/2022
Next Earnings (Estimated)
2/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.39 out of 5 stars

Medical Sector

201st out of 1,417 stocks

Pharmaceutical Preparations Industry

85th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -












Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

Is Supernus Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Supernus Pharmaceuticals stock.
View analyst ratings for Supernus Pharmaceuticals
or view top-rated stocks.

How has Supernus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SUPN shares have increased by 79.7% and is now trading at $29.02.
View which stocks have been most impacted by COVID-19
.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Supernus Pharmaceuticals
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted its earnings results on Wednesday, November, 3rd. The specialty pharmaceutical company reported $0.40 earnings per share for the quarter, beating analysts' consensus estimates of $0.21 by $0.19. The specialty pharmaceutical company had revenue of $148.46 million for the quarter, compared to analysts' expectations of $141.32 million. Supernus Pharmaceuticals had a net margin of 14.49% and a trailing twelve-month return on equity of 10.56%. During the same quarter in the prior year, the business posted $0.74 earnings per share.
View Supernus Pharmaceuticals' earnings history
.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals updated its FY 2021 earnings guidance on Wednesday, November, 17th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $550 million-$570 million, compared to the consensus revenue estimate of $560.68 million.

What price target have analysts set for SUPN?

2 analysts have issued 12-month price objectives for Supernus Pharmaceuticals' shares. Their forecasts range from $35.00 to $44.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $39.50 in the next twelve months. This suggests a possible upside of 36.1% from the stock's current price.
View analysts' price targets for Supernus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the following people:
  • Jack A. Khattar, President, CEO, Secretary & Director
  • Timothy C. Dec, Chief Financial Officer & Senior Vice President
  • Frank Mottola, Senior VP-Quality, GMP Operations & IT
  • Padmanabh P. Bhatt, Chief Scientific Officer & Senior Vice President
  • Jonathan Rubin, Chief Medical Officer & Senior Vice President

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals CEO Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among Supernus Pharmaceuticals' employees.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (1.17%), Scout Investments Inc. (0.68%), Tributary Capital Management LLC (0.61%), Isthmus Partners LLC (0.10%), Exchange Traded Concepts LLC (0.09%) and Prairiewood Capital LLC (0.08%). Company insiders that own Supernus Pharmaceuticals stock include Frederick M Hudson, Gregory S Patrick, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends for Supernus Pharmaceuticals
.

Which institutional investors are selling Supernus Pharmaceuticals stock?

SUPN stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Franklin Street Advisors Inc. NC, Scout Investments Inc., Vigilare Wealth Management, State of Alaska Department of Revenue, and Prairiewood Capital LLC.
View insider buying and selling activity for Supernus Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Supernus Pharmaceuticals stock?

SUPN stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Isthmus Partners LLC, Exchange Traded Concepts LLC, Eagle Bay Advisors LLC, and Campbell Newman Asset Management Inc..
View insider buying and selling activity for Supernus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $29.02.

How much money does Supernus Pharmaceuticals make?

Supernus Pharmaceuticals has a market capitalization of $1.53 billion and generates $520.40 million in revenue each year. The specialty pharmaceutical company earns $126.95 million in net income (profit) each year or $1.51 on an earnings per share basis.

How many employees does Supernus Pharmaceuticals have?

Supernus Pharmaceuticals employs 563 workers across the globe.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is www.supernus.com.

Where are Supernus Pharmaceuticals' headquarters?

Supernus Pharmaceuticals is headquartered at 1550 E GUDE DR, ROCKVILLE MD, 20850.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at (301) 838-2500, via email at [email protected], or via fax at 301-838-2501.


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.